Syngene International, a leading contract research, development, and manufacturing organization (CRDMO) based in India, has signed a partnership with Johns Hopkins University to advance early-stage drug discovery initiatives. The collaboration, announced in early 2026, aims to bridge academic innovation with industrial-scale capabilities to bring promising therapeutic concepts closer to the clinic.

Johns Hopkins, renowned for its cutting-edge biomedical research, generates a steady stream of novel targets and mechanisms in areas such as cancer, neurodegenerative disorders, immunology, and rare genetic conditions. Syngene will support these programs by offering integrated services across the discovery continuum from assay development and high-throughput screening to medicinal chemistry, in vitro/in vivo pharmacology, and preclinical safety assessments.

The partnership utilizes Syngene’s advanced discovery infrastructure, including AI-driven target identification, fragment-based drug design, and automated synthesis platforms. It also draws on Syngene’s experience in handling complex modalities such as small molecules, biologics, and PROTACs, allowing Johns Hopkins researchers to move quickly from hypothesis to lead compounds.

This alliance reflects a growing trend of academic institutions partnering with Indian CRDMOs to overcome resource and timeline constraints in early drug discovery. By combining Johns Hopkins’ deep scientific insight with Syngene’s scalable, cost-effective execution, the collaboration is expected to produce higher-quality candidates and accelerate the path to IND filing.

Both organizations emphasized a shared commitment to scientific rigor, intellectual property protection, and ultimately delivering new medicines to patients with high unmet needs.